Om

Nanjing Leads Biolabs Co., Ltd. is a clinical-stage biotechnology company specializing in the discovery, development, and commercialization of innovative therapeutic antibodies. With a diversified pipeline, the company focuses on next-generation immunotherapies designed to address unmet medical needs in oncology, autoimmune diseases, and other major health conditions. Its research encompasses monoclonal antibodies, bispecific T-cell engagers, antibody-drug conjugates, and fusion proteins, reflecting a robust and technologically advanced portfolio. Nanjing Leads Biolabs is recognized for rapid advancement from early-stage discovery to investigational new drug applications, leveraging proprietary platforms such as LeadsBody™ for CD3 T-cell engagement and X-body™ for 4-1BB activation. The company has achieved key milestones, including securing U.S. FDA Orphan Drug Designation and Breakthrough Therapy recognition in China for several of its assets. Its integrated, science-driven approach allows for seamless progression from preclinical research through clinical trials, positioning Nanjing Leads Biolabs as an emerging leader in the development of transformative immunotherapies within the biopharmaceutical sector.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I NANJING LEADS BIOLABS CO MED ENDAVU: Køb Nanjing Leads Biolabs Co ($9887) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Nanjing Leads Biolabs Co, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.